secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lakewood-Amedex Biotherapeutics Inc. (LABT)
CIK:        0002079272
Form:       8-K
Filed at:   2026-07-15T20:15:21+00:00
Accession:  0001213900-26-078328
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lakewood-Amedex releases investor deck on Bisphosphocin platform and Nu-3 gel for diabetic foot ulcers
--------------------------------------------------------------------------------

- Investor deck highlights Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials.
- Lead program Nu-3 is a topically delivered antimicrobial gel for infected diabetic foot ulcers (iDFU).
- Deck includes preclinical/clinical data, regulatory strategy, intellectual property, and competitive landscape.
- Presentation is for use in meetings with investors, analysts, and third parties; no material financial updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/0001213900-26-078328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/ea0297963-8k_lakewood.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-078328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer